Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:32:58 EDT Sun 20 Apr 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for C:MDNA from 2024-04-19 to 2025-04-18 - 35 items News ReleasesIn The NewsOther CAUS
DateSymCompanyPriceTypeHeadline
2025-04-01 07:00C:MDNAMEDICENNA THERAPEUTICS CORP. J0.98News ReleaseMedicenna to Present at Jones Healthcare and Technology Innovation Conference
2025-03-26 15:24C:MDNAMedicenna Therapeutics Corp0.99News ReleaseMedicenna to present MDNA11 update at AACR
2025-02-25 15:46C:MDNAMedicenna Therapeutics Corp1.13News ReleaseMedicenna talks MDNA11 Ability-1 study data
2025-02-13 10:28C:MDNAMEDICENNA THERAPEUTICS CORP. J1.27News ReleaseMedicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
2025-02-12 21:03C:MDNAMedicenna Therapeutics Corp1.27SEDAR Interim MD & ASEDAR Interim MD & A
2025-02-05 07:00C:MDNAMEDICENNA THERAPEUTICS CORP. J1.26News ReleaseMedicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
2024-12-13 08:30C:MDNAMEDICENNA THERAPEUTICS CORP. J1.81News ReleaseMedicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
2024-12-05 07:35C:MDNAMEDICENNA THERAPEUTICS CORP. J1.66News ReleaseMedicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA(TM) (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
2024-11-27 07:00C:MDNAMEDICENNA THERAPEUTICS CORP. J1.77News ReleaseUpdated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
2024-11-25 07:30C:MDNAMEDICENNA THERAPEUTICS CORP. J1.57News ReleaseMedicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)
2024-11-15 07:30C:MDNAMEDICENNA THERAPEUTICS CORP. J1.70News ReleaseMedicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
2024-11-14 19:42C:MDNAMedicenna Therapeutics Corp1.70SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-14 19:42C:MDNAMedicenna Therapeutics Corp1.70SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-11 11:31C:MDNAMedicenna Therapeutics Corp2.22News ReleaseMedicenna talks MDNA11 Ability-1 study results
2024-11-08 10:00C:MDNAMEDICENNA THERAPEUTICS CORP. J2.47News ReleaseMedicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2024-10-15 07:00C:MDNAMEDICENNA THERAPEUTICS CORP. J2.23News ReleaseOTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
2024-09-26 18:27C:MDNAMedicenna Therapeutics Corp1.88News ReleaseMedicenna Therapeutics holders approve AGM resolutions
2024-09-09 16:40C:MDNAMedicenna Therapeutics Corp2.22News ReleaseMedicenna presents preclinical results in France
2024-08-27 07:00C:MDNAMEDICENNA THERAPEUTICS CORP. J2.16News ReleaseMedicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
2024-08-15 15:46C:MDNAMedicenna Therapeutics Corp2.13News ReleaseMedicenna Therapeutics appoints Lalji to board
2024-08-01 07:00C:MDNAMEDICENNA THERAPEUTICS CORP. J2.13News ReleaseMedicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
2024-07-31 21:27C:MDNAMedicenna Therapeutics Corp2.13SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-07-31 21:27C:MDNAMedicenna Therapeutics Corp2.13SEDAR Interim MD & ASEDAR Interim MD & A
2024-07-26 16:52C:MDNAMedicenna Therapeutics Corp2.22MiscellaneousMedicenna Therapeutics has change in transfer agent
2024-06-27 18:36C:MDNAMedicenna Therapeutics Corp1.98News ReleaseMedicenna's March 31 cash position at $17-million
2024-06-27 00:52C:MDNAMedicenna Therapeutics Corp2.07SEDAR Annual Information FormSEDAR Annual Information Form
2024-06-27 00:39C:MDNAMedicenna Therapeutics Corp2.07SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2024-06-27 00:39C:MDNAMedicenna Therapeutics Corp2.07SEDAR MD & ASEDAR MD & A
2024-06-26 12:40C:MDNAMedicenna Therapeutics Corp2.07News ReleaseMedicenna receives EMA approval for Ability-1 trial
2024-06-03 12:30C:MDNAMedicenna Therapeutics Corp2.57News ReleaseMedicenna presents phase 2b bizaxofusp results at ASCO
2024-05-13 11:55C:MDNAMedicenna Therapeutics Corp2.47News ReleaseMedicenna denies breaking ASCO prior-publication policy
2024-04-30 14:50C:MDNAMedicenna Therapeutics Corp2.31News ReleaseMedicenna closes $20M investment from RA Capital
2024-04-26 09:09C:MDNAMedicenna Therapeutics Corp2.49News ReleaseMedicenna arranges $20M private placement
2024-04-26 08:09C:MDNAMedicenna Therapeutics Corp1.95Resume TradingMedicenna Therapeutics resuming at the open
2024-04-26 08:02C:MDNAMedicenna Therapeutics Corp1.95Halt TradingMedicenna Therapeutics halted at the open